Urinary Tract Infection Clinical Trial
Official title:
Urinary Proanthocyanidin (PAC) A2 as a Biomarker of Compliance to Intake of Cranberry Products - A Pilot Study
This protocol is a clinical trial to validate proanthocyanidin A2 (PAC-A2) as a useful marker of cranberry intake. We hypothesize the consumption of this cranberry beverage in a progressive dosing schedule will increase PAC-A2 excretion in urine. Five generally healthy, nonsmoking, pre-menopausal women (absent major chronic diseases including cardiovascular, endocrine, gastrointestinal, and renal conditions), age 20-40 years, with a body mass index (BMI) of 18.5-25 kg/m2 will be recruited from the Boston area because sexually active women in this age range are particularly vulnerable to urinary tract infection. Volunteers will be asked to consume their assigned cranberry beverage at a dose of 8 oz/day according to a weekly dosing schedule. Relevant clinical information and eleven 24-hour and morning spot urine samples each will be collected from subjects during the study. Urinary PAC-A2 concentration will then be determined to validate if it can serve as a marker of compliance of cranberry juice consumption.
Status | Completed |
Enrollment | 5 |
Est. completion date | April 2014 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: - generally healthy premenopausal women - aged 20-40 y - body mass index (BMI): 18.5-25 kg/m2 - sexually active but not pregnant or planning to become pregnant - no advance plans to discontinue use of hormonal contraceptives if they are taken Exclusion Criteria: - Use of medications known to affect lipid metabolism - History of a bilateral mastectomy - Use of medications known or suspected to influence blood pressure - cardiovascular diseases - Gastrointestinal diseases, - Renal or chronic kidney disease - Endocrine disorders - Rheumatologic diseases - Immune deficiency conditions - Active treatment for cancer of any type longer than 1 y - Systolic blood pressure >139 mmHg and/or diastolic blood pressure >89 mmHg - Regular use (more than 1x/wk) of any acid-lowering medications, laxatives (including fiber supplements) or anti-diarrheal medications - Use of any antibiotics in the last month - Regular use of systemic steroids, oral or injectable - Gain or loss of more than 5% of body weight in the last 6 mo - Any history of or known allergies to cranberries or cranberry products - Regular use of any dietary supplements containing vitamins, minerals, herbal or other plant-based preparations, fish oil supplements or homeopathic remedies. - Usual daily ethanol intake of equal and more than 2 drinks - Cigarette smoking and/or nicotine replacement use. - Strict vegetarians (vegans) - Pregnancy - Infrequent (<3/wk) or excessive (>3/d) number of regular bowel movements - Inability to discontinue or refrain from ASA/NSAID or Tylenol use for 72 h prior to and for the duration of testing on Visits 2-13 - Participation in a clinical research trial within 60 d of their enrollment visit (Visit 2) - Specific laboratory blood or urine analysis parameters of: Creatinine >1.5 mg/dL, Electrolytes, calcium, phosphorous - out of normal ranges, ALT and AST >1.5 nmol, Total bilirubin - above normal range, Fasting glucose =126 mg/dL, Total cholesterol >239 mg/dL, Triglycerides =300 mg/dL, CBC: HCT <32% for females, below normal range for males, WBC, PLT - out of normal range, hematuria, proteinuria |
Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United States | Jean Mayer USDA Human Nutrition Research Center on Aging | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Tufts University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proanthocyanidin A2 | proanthocyanidin A2 concentration in urine is determined using a LC-MS/MS method. | 24-hour urine and morning spot urine | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03235947 -
Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients
|
Phase 4 | |
Terminated |
NCT02198833 -
Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection
|
N/A | |
Withdrawn |
NCT01881165 -
Cranberry on Urinary Tract Infections
|
Phase 4 | |
Completed |
NCT02357758 -
Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
|
Phase 4 | |
Completed |
NCT01391793 -
Corticosteroids for Children With Febrile Urinary Tract Infections
|
Phase 3 | |
Completed |
NCT01219595 -
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
|
N/A | |
Completed |
NCT00365430 -
SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes
|
N/A | |
Recruiting |
NCT04502095 -
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
|
Phase 4 | |
Completed |
NCT00976963 -
Single Dose Monurol for Treatment of Acute Cystitis
|
N/A | |
Recruiting |
NCT02568800 -
Prolonged Infusion Cefepime and Nosocomial Infections
|
Phase 3 | |
Completed |
NCT02785445 -
Healthy.io Method Comparison & User Performance Study
|
N/A | |
Completed |
NCT02216253 -
L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection.
|
N/A | |
Completed |
NCT01478620 -
Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)
|
Phase 3 | |
Completed |
NCT01054690 -
Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI)
|
N/A | |
Completed |
NCT00371631 -
Colonizing Neurogenic Bladders With Benign Flora
|
Phase 1 | |
Terminated |
NCT03697993 -
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)
|
Phase 4 | |
Terminated |
NCT01803919 -
Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients
|
N/A | |
Enrolling by invitation |
NCT01231737 -
Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)
|
Phase 2 | |
Completed |
NCT01763008 -
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
|
Phase 4 | |
Completed |
NCT00528476 -
Risk Factors for Recurrent Urinary Tract Infection in Children
|
N/A |